SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Rossari Biotech - Quaterly Results

19 May 2022 Evaluate
The sales figure stood at Rs. 2616.41 millions for the March 2022 quarter. The mentioned figure indicates a growth of about 29.86% as compared to Rs. 2014.82 millions during the year-ago period.The Company's Net profit for the March 2022 quarter have declined marginally to Rs. 168.74  millions as against Rs. 213.99 millions reported during the corresponding quarter ended.A decline of 294.01 millions was observed in the OP in the quarter ended March 2022 from 369.58 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 2616.41 2014.82 29.86 10728.44 6904.14 55.39 10728.44 6904.14 55.39
Other Income 19.35 16.97 14.02 127.00 97.23 30.62 127.00 97.23 30.62
PBIDT 294.01 369.58 -20.45 1354.93 1310.64 3.38 1354.93 1310.64 3.38
Interest 6.05 8.04 -24.75 25.45 29.92 -14.94 25.45 29.92 -14.94
PBDT 287.96 361.54 -20.35 1329.48 1280.72 3.81 1329.48 1280.72 3.81
Depreciation 70.80 69.36 2.08 262.68 220.74 19.00 262.68 220.74 19.00
PBT 217.16 292.18 -25.68 1066.80 1059.98 0.64 1066.80 1059.98 0.64
TAX 48.42 78.19 -38.07 272.06 268.96 1.15 272.06 268.96 1.15
Deferred Tax -11.06 -3.64 203.85 -15.09 -6.34 138.01 -15.09 -6.34 138.01
PAT 168.74 213.99 -21.15 794.74 791.02 0.47 794.74 791.02 0.47
Equity 110.11 103.86 6.02 110.11 103.86 6.02 110.11 103.86 6.02
PBIDTM(%) 11.24 18.34 -38.74 12.63 18.98 -33.47 12.63 18.98 -33.47

Rossari Biotech Share Price

478.75 10.95 (2.34%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 3640.10
Tata Chemicals 809.45
SRF 2519.20
Pidilite Inds. 1375.55
Deepak Nitrite 1736.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×